Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Rezolute (Nasdaq: RZLT) has appointed Erik Harris to its Board of Directors, effective immediately. Harris, currently serving as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings over 20 years of biopharmaceutical expertise to the company.
Harris has significant experience in global product launches, building commercial teams, and developing strategic partnerships. His appointment comes at a important time as Rezolute advances its lead programs through clinical development and prepares for potential commercialization, particularly focusing on ersodetug for hyperinsulinism treatment.
Rezolute (Nasdaq: RZLT) ha nominato Erik Harris nel suo Consiglio di Amministrazione, con effetto immediato. Harris, attualmente Chief Commercial Officer e Vicepresidente Esecutivo di Ultragenyx, porta con sé oltre 20 anni di esperienza nel settore biofarmaceutico.
Harris ha una significativa esperienza in lanci di prodotti a livello globale, nella costruzione di team commerciali e nello sviluppo di partnership strategiche. La sua nomina arriva in un momento importante, poiché Rezolute sta portando avanti i suoi programmi principali attraverso lo sviluppo clinico e si prepara per una potenziale commercializzazione, concentrandosi in particolare su ersodetug per il trattamento dell'iperinsulinemia.
Rezolute (Nasdaq: RZLT) ha nombrado a Erik Harris en su Junta Directiva, con efecto inmediato. Harris, que actualmente se desempeña como Director Comercial y Vicepresidente Ejecutivo en Ultragenyx, aporta más de 20 años de experiencia en el sector biofarmacéutico.
Harris tiene una experiencia significativa en lanzamientos de productos a nivel global, construcción de equipos comerciales y desarrollo de asociaciones estratégicas. Su nombramiento llega en un momento importante, ya que Rezolute avanza en sus programas principales a través del desarrollo clínico y se prepara para una posible comercialización, enfocándose particularmente en ersodetug para el tratamiento de la hiperinsulinemia.
레졸루트 (Nasdaq: RZLT)는 에릭 해리스를 이사회에 즉시 임명했습니다. 해리스는 현재 울트라제닉스의 최고 상업 책임자 및 전무 이사로 재직 중이며, 20년 이상의 생물 제약 분야 전문 지식을 회사에 제공합니다.
해리스는 글로벌 제품 출시, 상업 팀 구축 및 전략적 파트너십 개발에 대한 상당한 경험을 보유하고 있습니다. 그의 임명은 레졸루트가 임상 개발을 통해 주요 프로그램을 진행하고, 특히 고인슐린혈증 치료를 위한 ersodetug의 상업화 가능성을 준비하는 중요한 시점에 이루어졌습니다.
Rezolute (Nasdaq: RZLT) a nommé Erik Harris à son Conseil d'Administration, avec effet immédiat. Harris, qui occupe actuellement le poste de Directeur Commercial et Vice-Président Exécutif chez Ultragenyx, apporte plus de 20 ans d'expertise dans le domaine bio-pharmaceutique.
Harris possède une expérience significative en lancements de produits à l'échelle mondiale, en construction d'équipes commerciales et en développement de partenariats stratégiques. Sa nomination intervient à un moment important, alors que Rezolute fait progresser ses programmes principaux à travers le développement clinique et se prépare à une éventuelle commercialisation, en se concentrant particulièrement sur ersodetug pour le traitement de l'hyperinsulinisme.
Rezolute (Nasdaq: RZLT) hat Erik Harris sofort in seinen Vorstand berufen. Harris, der derzeit als Chief Commercial Officer und Executive Vice President bei Ultragenyx tätig ist, bringt über 20 Jahre Erfahrung im Bereich der biopharmazeutischen Industrie mit.
Harris hat umfangreiche Erfahrungen in globalen Produkteinführungen, dem Aufbau von Vertriebsteams und der Entwicklung strategischer Partnerschaften. Seine Ernennung erfolgt zu einem wichtigen Zeitpunkt, da Rezolute seine Hauptprogramme durch die klinische Entwicklung vorantreibt und sich auf eine mögliche Kommerzialisierung vorbereitet, insbesondere mit dem Fokus auf ersodetug zur Behandlung von Hyperinsulinismus.
- Appointment of experienced commercial leader with 20+ years of biopharmaceutical expertise
- Strategic addition to support commercialization preparation
- Ersodetug showing positive results in hyperinsulinism treatment
- None.
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute.
“We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for potential commercialization,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “Erik brings a unique blend of strategic vision, operational excellence, and dedication to serving the needs of patients and their families.”
Mr. Harris is an experienced board member and commercial leader with a proven track record in the industry. Mr. Harris has spearheaded global product launches, built and led high-performing commercial teams, and fostered strategic partnerships while navigating complex markets and achieving ambitious growth targets.
“I'm excited to join the Rezolute board at such a pivotal time,” said Mr. Harris. “I'm very impressed with the company's evolution and believe that ersodetug has already demonstrated the ability to significantly improve the quality of life for individuals with hyperinsulinism. I look forward to helping guide the company in the next phase of its development.”
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, statements regarding the ability of ersodetug to become an effective treatment for congenital hyperinsulinism and statements regarding the potential regulatory approval and commercialization of ersodetug. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the SEC’s website at www.sec.gov. You are urged to consider these factors carefully by evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Contacts:
Investors
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Media
Sarah Lima
Sarah@GalvinPR.com
(774) 766-0200
FAQ
Who is the new board member appointed to Rezolute (RZLT) in March 2025?
What experience does Erik Harris bring to Rezolute's (RZLT) board?
How will Erik Harris's appointment benefit Rezolute's (RZLT) development plans?
What is the current status of Rezolute's (RZLT) ersodetug program?
